Content
All Posts > Content under Pharma/Biotech
Clovis: Evaluating The Prospects Of A Possible Acquisition
Article By:
Dr. Hung Tran
Read
Thursday, January 16, 2020 9:27 AM EDT
Riding robust data, Rubraca is most likely to gain approval for resistant prostate cancer having the BRCA mutation. Here I present a scientific analysis to merger and acquisition to give you more insight into Clovis.
Organigram Reports Impressive Q1 Financials - Stock Responds
Article By:
Lorimer Wilson
Read
Wednesday, January 15, 2020 6:34 PM EDT
Organigram Holdings Inc. results for the first quarter ended November 30, 2019, showed impressive improvement in almost all of its numbers from the previous quarter, as follows:
How Expensive Are ESG Stocks?
Article By:
AllAboutAlpha
Read
Sunday, January 12, 2020 8:31 PM EDT
Europeans seem far more focused on the environment than Americans. It is therefore not surprising that 46% of European investors have allocated to ESG, compared with only 28% of Americans, according to survey results from JP Morgan.
Top Picks 2020: Anavex
Article By:
MoneyShow.com
Read
Saturday, January 11, 2020 9:00 PM EDT
This little known, yet promising, bio-pharmaceutical company is worthy of a closer look.
In this article: AVXL
Week In Review: Four China Biopharmas Announce $100+ Million Deals In First Week Of 2020
Article By:
ChinaBio® Today
Read
Saturday, January 11, 2020 4:11 PM EDT
Apollomics of Hangzhou announced a $189 million agreement to develop two GlycoMimetics novel E-selectin-based immunotherapies in China for leukemia. Apollomics will be responsible for developing uproleselan and GMI-1687.
The 10 Best-Performing Micro-Cap Stocks Of 2019
Article By:
SureDividend
Read
Saturday, January 11, 2020 11:01 AM EDT
In 2019 the S&P 500 Index rose an astounding 29%. Much of that gain is the result of a horrible end to 2018 that saw stocks bottom the day before Christmas. Here were the 10 best-performing micro-cap stocks of 2019.
Big Tech Will Be Both Friend And Foe To Big Pharma
Article By:
Lipper Alpha Insight
Read
Wednesday, January 8, 2020 5:50 AM EDT
The new technology could help drug companies develop better therapies – and charge more for them.
In this article: GOOGL
Top Performing ETFs Of The Decade
Article By:
Neena Mishra
Read
Tuesday, January 7, 2020 4:35 PM EDT
Growth stocks have significantly outperformed their value peers during the decade, as investors have been chasing growth at any price. Among the sectors, Technology was the best performer and Energy was the worst.
Cannabis Central: December Market Performance Sliced & Diced By Category
Article By:
Lorimer Wilson
Read
Tuesday, January 7, 2020 3:27 PM EDT
Every month I analyze the performance of six marijuana categories to unveil the strengths and weaknesses of their components and December saw the returns of those categories range from +10.1% to -15.9% versus +1.0% for the overall marijuana market.
